Literature DB >> 14751841

Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen.

Michael Lahn1, Karen Sundell, Stephanie Moore.   

Abstract

Antisense oligonucleotides (ASOs) offer a novel pharmacological platform to develop highly specific drugs. As shown by the clinical development of aprinocarsen, an ASO directed against protein kinase C-alpha (PKC-alpha), this platform has made a remarkable advance from the bench to the bedside. This review summarizes the rationale of the early development of aprinocarsen and current clinical experience.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14751841     DOI： 10.1196/annals.1281.029

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

Review 2.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

3.  Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.

Authors:  Johan Vansteenkiste; Jean-Luc Canon; Henrik Riska; Robert Pirker; Patrick Peterson; William John; Pekka Mali; Michael Lahn
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

Review 4.  Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.

Authors:  Zhongwei Liu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

5.  Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis.

Authors:  Carrie A Franzen; Chih-Chiun Chen; Viktor Todorović; Vladislava Juric; Ricardo I Monzon; Lester F Lau
Journal:  Mol Cancer Res       Date:  2009-07-07       Impact factor: 5.852

Review 6.  Protein kinase C, an elusive therapeutic target?

Authors:  Daria Mochly-Rosen; Kanad Das; Kevin V Grimes
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

Review 7.  The complexities of PKCα signaling in cancer.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Adv Biol Regul       Date:  2020-11-23

Review 8.  Protein kinase C isoforms: Multi-functional regulators of cell life and death.

Authors:  Mary E Reyland
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.